LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

Halozyme Therapeutics Inc

Fechado

SetorSaúde

73.23 0.56

Visão Geral

Variação de preço das ações

24h

Atual

Mín

72.97

Máximo

73.24

Indicadores-chave

By Trading Economics

Rendimento

47M

165M

Vendas

61M

326M

P/E

Médio do Setor

16.524

35.724

EPS

1.54

Margem de lucro

50.706

Funcionários

350

EBITDA

61M

230M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

-3.54% downside

Dividendos

By Dow Jones

Próximos Ganhos

30 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.1B

8.4B

Abertura anterior

72.67

Fecho anterior

73.23

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Halozyme Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de mar. de 2025, 19:42 UTC

Principais Notícias

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 de mar. de 2025, 10:30 UTC

Principais Notícias

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

1 de nov. de 2024, 11:30 UTC

Principais Notícias

S&P 500 Futures Climb In Premarket Trading; Atlassian, XP Lead

Comparação entre Pares

Variação de preço

Halozyme Therapeutics Inc Previsão

Preço-alvo

By TipRanks

-3.54% parte inferior

Previsão para 12 meses

Média 70.56 USD  -3.54%

Máximo 91 USD

Mínimo 51 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

9 ratings

5

Comprar

3

Manter

1

Vender

Pontuação Técnica

By Trading Central

60.49 / 70.14Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.